Overview

A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2025-08-08
Target enrollment:
Participant gender:
Summary
This study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WM-S1-030 in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Wellmarker Bio
Collaborator:
Covance